tivity to very lipid soluble agents but have little or no increases to other agents. In addition, a class of extragenic suppressor mutations exists that suppresses some altered sensitivities but specifically does not suppress the altered sensitivity to diethyl ether. There is much debate concerning the molecular nature of the site(s) of anesthetic action. One point of discussion is whether the site(s) consists of a purely lipid binding site or if protein is involved. The simplest explanation of our observations is that volatile anesthetics cause immobility in C. elegans by specifically interacting with multiple sites. This model is in turn more consistent with involvement of protein at the site(s) of action.
More than a century has passed since the introduction of volatile anesthetics, yet the site and mechanism of action of volatile anesthetics remain unknown. Meyer (1) and Overton (2) showed that the potency of volatile anesthetics depended solely on their oil solubilities, despite widely varying chemical structures. This relationship is termed the MeyerOverton relationship. A second characteristic of anesthetics is that, in general, they are directly additive in their effects (3) . These findings have led to two main conclusions about the sites of action of volatile anesthetics. (i) Volatile anesthetics work at a single lipophilic site to cause anesthesia. ( ii) The site of action has properties similar to the lipid used to determine the oil-gas partition coefficient. In addition, the number of anesthetic molecules required at the site of action to cause anesthesia is a constant regardless of the anesthetic used (4) . The identification ofthe site ofaction ofthese agents would seem to be a prerequisite for understanding their mode of action.
The nematode Caenorhabditis elegans appears to be a good model for the study of volatile anesthetics (5) . The wild-type strain N2 responds to volatile anesthetics in a manner similar to all other species including humans: it follows the Meyer-Overton relationship (5) and exhibits additivity between anesthetics (P.G.M. and M.S., unpublished results). The behavioral pattern during exposure to anesthetics resembles that of more complex organisms. At low doses of anesthetic the animals become "excited," moving more than animals not exposed to anesthetics. As the anesthetic concentrations are increased, the animals next become very uncoordinated, and at higher doses they are immobilized. When removed from the anesthetics the nematodes quickly regain mobility and return to their normal phenotype. Mutations in two genes, unc-79 and unc-80, confer altered responses to volatile anesthetics, in addition to an altered motor phenotype. When not in the presence of anesthetics, both these mutants are described as "fainters." Their motion consists of short periods of normal motion, followed by an apparent refractory period lasting a few seconds during which their locomotion ceases (6, 7) . At least one allele of unc-79 has been shown to be suppressed by an amber suppressor and thus represents a loss-of-function allele. These mutants have increased sensitivity to one group of anesthetics (thiomethoxyflurane, methoxyflurane, chloroform, and halothane; group 1), decreased sensitivity to a second group (enflurane and flurothyl; group 2), and no change in sensitivity to a third group (isoflurane and fluroxene; group 3). In addition, both mutations confer a mild increase in sensitivity to diethyl ether, the sole member of group 4. This increase is quantitatively different than the increase seen in group 1 (Fig. 1) . We postulated that these mutations affect the site of action of volatile anesthetics (7) . We have screened 105 uncoordinated mutants in C. elegans, in addition to screens of newly mutagenized nematodes, and have not identified other single-gene mutations that alter responses to volatile anesthetics (P.G.M. and M.S., unpublished results). Thus, it appears that the mechanisms controlling the response of C. elegans to volatile anesthetics will be genetically tractable and involve relatively few genes with major effects.
Another method for identification of gene products affecting the site ofaction ofvolatile anesthetics is the study ofgene interaction (6, 8) . If several gene products function together at a particular site, then mutations in a second gene may alter or compensate for mutations in an initial gene (9) . The phenotypes of double mutants could provide valuable information about such interactions. We have studied a class of genetic interaction known as indirect suppression.
Mutations in unc-79 and unc-80 are more sensitive to halothane than is the wild type. Sedensky and Meneely (6) described mutations in the gene unc-9 that suppressed the abnormal response of unc-79 and unc-80 to halothane. The double mutants, unc-79;unc-9 and unc-80;unc-9, exhibit normal sensitivity to halothane. unc-9 alone also has normal sensitivity to halothane and, when not in the presence of anesthetics, has a motion described as kinked. The mechanism by which unc-9 exerts its effects is unknown. The effect of unc-9 on unc-79 and unc-80 had only been studied for halothane. In this article we describe the effect of unc-9 on the responses of unc-79 and unc-80 to nine anesthetics. We tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. also describe here the identification of two suppressors of unc-79 and unc-80. These mutants, unc-J and unc-7, have uncoordinated phenotypes very similar to that of unc-9, described as kinked or curly (10) . unc-7 was initially studied because an allele, nc933, was mistakenly thought to be an unc-9 allele. unc-J (e538) was originally studied as a negative kinked control for some unc-9 experiments, only to demonstrate suppression activity itself. We determined the effects of these suppressors on the response of unc-79 and unc-80 to halothane. We then studied the effects of the unc-J and unc-7 mutations on the responses of unc-79 to a representative anesthetic from each of the four groups described above. We postulated that if these mutations alter the site(s) of anesthetic action, then there may exist differences in the quality or quantity of suppression for different anesthetics. Such differences may give insight to the nature of the site of action of volatile anesthetics in C. elegans.
Previous work has also shown that four classes of mutations exist in the unc-J gene (11 raising, handling, and performing genetic crosses with C. elegans have been described elsewhere in detail (12) .
Dose-Response Curves. Procedures for exposing nematodes to anesthetics, scoring their responses, and measuring anesthetic concentrations have also been described in detail (8) . Concentrations of anesthetics were expressed in percent volume (vol %) at standard temperature and pressure in air. ED50 values were the percent volumes at which 50% of the animals were immobile for greater than 10 sec.
Anesthetics. Thiomethoxyflurane was kindly provided by E. I. Eger II (Department of Anesthesia, University of California, San Francisco). Methoxyflurane, chloroform, halothane, enflurane, isoflurane, diethyl ether, and fluroxene were commercial products. Halothane was supplied by Halocarbon Products (Hackensack, NJ). Enflurane, isoflurane, and flurothyl were supplied by Anaquest (Madison, WI). Diethyl ether was supplied by Fisher.
Statistical Methods. Regression analysis, ED50 values, and standard errors were calculated using the methods described by Waud (13) . For each anesthetic, the ED50 values of all four strains were compared using an analysis of variance to see if they satisfied the null hypothesis (P < 0.05). If Table 1 lists the ED50 values (mean ± SE) for six strains (N2, unc-79, unc-80, unc-9, and the double mutants unc-79; unc-9 and unc-80;unc-9) in nine volatile anesthetics. unc-79 and unc-80 show increased sensitivity to all four anesthetics in group I (thiomethoxyflurane, methoxyflurane, chloroform, and halothane) (7). However, the double mutants unc-79;unc-9 and unc-80;unc-9 have normal sensitivity to these agents. Thus, unc-9 suppresses the increased sensitivity of unc-79 and unc-80 to all agents in group I. unc-79 shows mild resistance to anesthetics in group II (enflurane and flurothyl). unc-9 also suppresses this mild resistance; i.e., the double mutant unc-79;unc-9 has normal sensitivity to these agents. unc-79 and unc-80 have normal sensitivities to anesthetics in group III (isoflurane and fluroxene) and unc-9 had no effect on their response to these agents. unc-79 and unc-80 exhibit mild increases in sensitivity to diethyl ether. unc-9 does not suppress this response. In fact, the double mutants unc-79;unc-9 and unc-80;unc-9 are more sensitive to diethyl ether than are the single mutants (Table 1 and Fig. 2) .
RESULTS
To determine if unc-J and unc-7 were suppressors of unc-79 and unc-80, we exposed strains containing unc-J or unc-7, instead of unc-9, to a representative from each of the four groups ofanesthetics. Table 2 lists the data for the strains unc-J(e719), unc-79;unc-1, unc-7(eS), and unc-79;unc-7. Table 3 lists the equivalent data for the strains involving unc-80-that is, unc-J, unc-80;unc-1, unc-7, and unc-80;unc-7. Both unc-J and unc-7 suppress the increased sensitivities ofunc-79 and unc-80 to halothane. Neither unc-J nor unc-7 suppress the increased sensitivities of unc-79 and unc-80 to diethyl ether. The resistance of unc-79 to enflurane is also suppressed by both unc-J and unc-7, whereas these mutations exert no significant effect on the sensitivity of unc-79 or unc-80 to isoflurane. Thus, the pattern of suppression for unc-J and unc-7 is the same as for unc-9.
The effect of each of the four classes of unc-1 mutations (11) on unc-79 is shown in Table 4 . The double mutants were screened in 2% halothane, a concentration that immobilizes 100o of either unc-79 or unc-80 but leaves N2 unaffected (6, 7). Each strain was scored for percent immobilized at this concentration. The data show that both classes of unc-J that are recessive in their kinked phenotype (represented by el14 and e580) are also recessive suppressors of unc-79 in halothane. The classes that are dominant in coiled phenotype (represented by n494 and n774) are not suppressors, as heterozygotes, of unc-79 in halothane. However, the representative of class 4, n774, exhibits a kinked phenotype as a homozygote, and, as a homozygote, it is a suppressor of unc-79 in halothane. The representative of class 3, n494, remains coiled as a homozygote. As a homozygote n494 does not suppress the altered sensitivity of unc-79 to halothane. Thus, the ability to suppress unc-79 in halothane follows exactly the kinked phenotype in unc-J. As with unc-9 and unc-7, none of the unc-J mutants alone alters halothane sensitivity.
DISCUSSION
We have characterized mutations in three genes that act as indirect suppressors of the responses of unc-79 and unc-80 to volatile anesthetics. Each of the suppressors followed the same pattern. Each mutation alone showed a normal response to the anesthetics tested. unc-1, unc-7, and unc-9 individually suppress the increased sensitivity of unc-79 and unc-80 to halothane. In addition, each one suppresses the decreased sensitivity of unc-79 to enflurane. None of the suppressors altered the normal response of unc-79 to isoflurane. In contrast to the suppressing activities noted above, however, none of the three mutations suppressed the increased sensitivity of unc-79 to diethyl ether. We must also note that unc-) and unc-7 were studied because of their resemblance to unc-9 and not picked up on independent screens for suppressors. We have also tested other kinked mutants, unc-2 and unc42, and found that they do not suppress unc-79. (P.G.M. and M.S., unpublished results). Thus, although the kinked phenotype correlates with the capability of unc-J to suppress unc-79, the kinked phenotype alone is not sufficient to confer the capability to suppress unc-79. It should be noted that the "kinked" phenotype may arise from a variety of neurological defects.
We have suggested (7) that unc-79 and unc-80 respond to volatile anesthetics as if multiple classes of volatile anesthetics exist. The three suppressors in this study affect the responses of unc-79 and unc-80 to some anesthetics but not to others. They also alter both increased sensitivities to some anesthetics and decreased sensitivities to others. We think that these results are best explained if multiple classes of volatile anesthetics exist. At the turn of the century Meyer (1) and Overton (2) independently noted that the potency of volatile anesthetics was related to their lipid solubility. This relationship has proved true in all organisms studied to date, including wildtype C. elegans (7) . The Meyer-Overton model for the action of volatile anesthetics implies that all such agents act by perturbing a site with certain lipophilic qualities. This model has been interpreted to further imply that all volatile anesthetics work at an identical site, with potencies depending only on lipophilic properties of the anesthetic. However, if such were the case, an increase in sensitivity to one anesthetic should be accompanied by similar changes to other anesthetics as well. For unc-79 and unc-80 we see such is not the case; these mutants exhibit large increases in sensitivity to some anesthetics and not to others. Further, in this study, we now show that one class of suppressors are able to suppress the altered sensitivities of unc-79 and unc-80 to some anesthetics but not to others.
The simplest explanation of these data is that all volatile anesthetics do not work at an identical site in C. elegans. We think at least three different sites must be affected in this organism (Table 5) . We should note that we are using the term "site" in a general sense. The different sites may actually be one locus that is perturbed in different manners by different anesthetics. Thus, different sites may refer to different types of interactions at only one location or may refer to physically different loci (or a combination of these possibilities). These different interactions may then be separable by mutation.
One such site appears to be altered strongly by the mutations unc-79 or unc-80 and suppressed by mutations in unc-J, unc-7, or unc-9. A second site is also altered by unc-79 or unc-80 but is not suppressed by unc-J, unc-7, or unc-9. A third site is unaffected or only slightly affected by the mutations unc-79 or unc-80. We are hesitant to separate sites based on the mild resistance of unc-79 to enflurane and flurothyl compared to the normal response of this mutant to isoflurane and fluroxene. Further work is necessary to determine if two separate sites are identified by these differences. Diethyl ether (group 4) Characteristics of three sites of action of volatile anesthetics in the nematode C. elegans. It is possible that site B may be subdivided based on the mild resistance of unc-79 to enflurane and flurothyl and the ability of unc-9 to suppress this resistance. We have elected not to make this distinction until genes strongly affecting such sites are identified.
Volatile anesthetics do have multiple effects in clinical practice, and these effects vary with different agents. For example, at equipotent anesthetic doses, halothane depresses respiration more than diethyl ether or fluroxene (15) ; enflurane is known to depress the seizure threshold, whereas halothane does not (16) . Many other clinical differences (i.e., skeletal muscle relaxation, cardiac contractility, or vasomotor tone) exist between these agents (17, 18) . This certainly implies that volatile anesthetics interact with many different sites. Recent neurophysiologic studies have also clearly documented that anesthetics have effects at different sites (19, 20) . However, these other effects do not follow the Meyer-Overton relationship. Ethanol and the benzodiazepines have been correlated with altered type A y-aminobutyric acid receptors (21, 22) . Altered sensitivity to volatile anesthetics has not been correlated with different channel or receptor mutations. It is unlikely that these volatile anesthetics work by mechanisms identical to those of ethanol and the benzodiazepines.
Other causes of the alterations seen in these mutants are possible. It may be that the mutations, unc-79 and unc-80, cause a structure, not initially sensitive to volatile anesthetics, to become sensitive and produce immobility at low doses of very-lipid-soluble anesthetics. We feel this possibility is unlikely since unc-79 and unc-80 also cause a decrease in sensitivity to enflurane and fluroxene. Since we will always measure the sensitivity of the most sensitive site, we must have altered the site originally sensitive to the last two agents in a manner decreasing their sensitivity. A How then does one resolve the altered responses seen here with the Meyer-Overton relationship? We believe the answer may be that anesthetics affect a family of structurally similar channels or regions in the cell membrane. Since many chemically and voltage-gated channels exist is similar membrane environments, it is not unreasonable that they may have similar structures that function within a lipid moiety. Several chemically gated channels have large regions with a high degree of amino acid homology (23) . The clinical differences among anesthetics may then reflect the preference of certain anesthetics for distinct members of such a family. However, the similarities between members of a family of channels may put them all at risk for disruption by any volatile anesthetic, at only slightly different concentrations. These small differences in sensitivity may be lost on a log-log plot; thus, hidden within a straight-line log-log plot multiple sites may be functioning. The correlation between lipid solubility and potency, interpreted as function at a single site, may actually arise from the function of volatile anesthetics at different, but similar, sites.
This information may cause a change in the strategies used to determine the neurophysiologic basis of anesthetic action. Instead of searching for one type of channel disrupted by all anesthetics in a pattern following the Meyer-Overton relationship, we suggest that a family of similar channels is more likely involved. These results do not entirely rule out the possibility of multiple membrane regions of similar fatty acid, cholesterol, etc., packing that contain differences sufficient to confer preferences for different volatile anesthetics. However, we believe that, given this type of specificity for different anesthetics, a more likely model involves interaction with a protein in a lipid moiety such as that suggested by Franks and Leib (24) .
Such a model may explain one of our observations. We have identified mutants with increased sensitivity to anesthetics but have been unable to identify single gene mutations conferring resistance to halothane (P.G.M. and M.S., unpublished results). If multiple sites are available as targets to cause immobility in C. elegans, then we will measure the effect on the most sensitive one. If we make only one site resistant by mutagenesis, we may merely unmask a second one that displays a sensitivity to anesthetics only slightly different from the original site. However, by searching for multiple mutants with two or more resistant sites, perhaps strains resistant to an anesthetic can be identified. Using unc-9 as an initial mutation, we have now identified strains with a second mutation conferring resistance to halothane. Neither mutation individually alters sensitivity to halothane.
In summary, we have identified a class of genes that suppresses the abnormal response of unc-79 and unc-80 to halothane and other anesthetics but specifically does not suppress the response to diethyl ether. The simplest explanation of these data is that volatile anesthetics cause immobility in C. elegans by interacting with more than one site and that a pure lipid binding model is unlikely.
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